Development of a first-in-class small molecule to treat epithelial ovarian cancer

Microquin LTD received a $299,200 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), with an award date of June 1, 2025 and completion date of August 31, 2026. The grant supports the development of a first-in-class small molecule therapeutic treatment for epithelial ovarian cancer, performed at the company's Cambridge, Massachusetts location. This research aligns with the DHA's mission to transform healthcare for military service members and the broader public through innovative biomedical solutions.

The award represents continued federal investment in Microquin LTD's oncology research capabilities. As a specialized biotechnology company, Microquin LTD has received seven prime federal grants totaling over $1.3 million from the DHA and Department of the Army Medical Command since 2022, demonstrating sustained support for the company's research and development services in cancer therapeutics and other critical medical conditions affecting military personnel.